Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from Rs13181

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Sep 25

PMID 39319218

Authors

Nadiya Nurul Afifah

Lanny Indah Permatasari

Ajeng Diantini

Ruri Intania

Indra Wijaya

Hideru Obinata

Melisa Intan Barliana

Affiliations

Soon will be listed here.

Abstract

Purpose: Individual responses to platinum-based treatment for Non-Small Cell Lung Cancer (NSCLC) are influenced by genetic polymorphisms, including Single Nucleotide Polymorphisms (SNPs). This study aimed to explore the role of ERCC2 in the Nucleotide Excision Repair (NER) pathway for platinum-based chemotherapy in NSCLC. While is widely studied, data for Southeast Asian populations are lacking. Addressing this gap could improve personalized treatment strategies for NSCLC in this demographic.

Patients And Methods: This study recruited 82 NSCLC patients with wildtype mutations of at Dr. H.A. Rotinsulu Lung Hospital, Bandung, and Dharmais Cancer Hospital, Jakarta. Data were collected prospectively from whole blood samples and medical records, while the effectiveness of chemotherapy was assessed by evaluating the response using RECIST 1.1 criteria on fourth cycle of chemotherapy.

Results: The results of this study showed the presence of genotype variation among the subjects, with frequency distribution as follows: AA genotype (82.9%), AC genotype (15.9%), and CC genotype (1.2%). The analysis of the association between rs13181 CC + AC versus AA with RECIST 1.1 yielded an odds ratio (OR) of 1.042 (95% CI: 0.292-3.715; p=0.950). A multivariate analysis that included cancer stage and chemotherapy regimen as additional variables produced an adjusted odds ratio (aOR) of 0.970 (95% CI: 0.263-3.568; p=0.963).

Conclusion: This study did not find statistically significant associations between rs13181 polymorphisms and chemotherapy responses. However, this research highlights the presence of genetic variation within the Indonesian population, with the AA genotype being the most prevalent, which may influence chemotherapy responses. The results provided preliminary data and lay the foundation for future comprehensive cohort observational investigations.

References

Gendarme S, Bylicki O, Chouaid C, Guisier F . Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Curr Oncol. 2022; 29(2):641-658. PMC: 8870726. DOI: 10.3390/curroncol29020057. View

Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L . Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017; 49(3). DOI: 10.1183/13993003.01520-2016. View

Sito H, Sharzehan M, Islam M, Tan S . Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis. Br J Biomed Sci. 2024; 81:11835. PMC: 10914946. DOI: 10.3389/bjbs.2024.11835. View

Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P . Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol. 2007; 2(8):735-40. DOI: 10.1097/JTO.0b013e31811f3a7d. View

Sagerup C, Smastuen M, Johannesen T, Helland A, Brustugun O . Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax. 2011; 66(4):301-7. DOI: 10.1136/thx.2010.151621. View

Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S . The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front Pharmacol. 2020; 11:343. PMC: 7100275. DOI: 10.3389/fphar.2020.00343. View

Torre L, Siegel R, Jemal A . Lung Cancer Statistics. Adv Exp Med Biol. 2015; 893:1-19. DOI: 10.1007/978-3-319-24223-1_1. View

Xu J, Huang H, Pan C, Zhang B, Liu X, Zhang L . Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells. Int J Oral Maxillofac Surg. 2007; 36(8):739-44. DOI: 10.1016/j.ijom.2007.05.016. View

Amable L . Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016; 106:27-36. DOI: 10.1016/j.phrs.2016.01.001. View

10.

El Shamieh S, Zgheib N . Pharmacogenetics in developing countries and low resource environments. Hum Genet. 2021; 141(6):1159-1164. DOI: 10.1007/s00439-021-02260-9. View

11.

Song X, Wang S, Hong X, Li X, Zhao X, Huai C . Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. Sci Rep. 2017; 7(1):11785. PMC: 5603542. DOI: 10.1038/s41598-017-08257-7. View

12.

Dasgupta P, Chellappan S . Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle. 2006; 5(20):2324-8. DOI: 10.4161/cc.5.20.3366. View

13.

Zappa C, Mousa S . Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3):288-300. PMC: 4931124. DOI: 10.21037/tlcr.2016.06.07. View

14.

Yang Y, Xian L . The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 2013; 35(4):2905-21. DOI: 10.1007/s13277-013-1493-5. View

15.

Tan L, Qiu C, Zhu T, Jin Y, Li X, Yin J . Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis. Sci Rep. 2017; 7(1):5593. PMC: 5514117. DOI: 10.1038/s41598-017-05642-0. View

16.

Gandara D, Mack P, Li T, Lara Jr P, Herbst R . [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010; 13(3):238-41. PMC: 6136060. DOI: 10.3779/j.issn.1009-3419.2010.03.16. View

17.

Wei S, Zhan P, Shi M, Shi Y, Qian Q, Yu L . Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2010; 28(1):315-21. DOI: 10.1007/s12032-010-9443-1. View

18.

Minna J . Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest. 2003; 111(1):31-3. PMC: 151841. DOI: 10.1172/JCI17492. View

19.

Dantoing E, Piton N, Salaun M, Thiberville L, Guisier F . Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int J Mol Sci. 2021; 22(12). PMC: 8230861. DOI: 10.3390/ijms22126288. View

20.

Tang N, Lyu D, Zhang Y, Liu H . Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis. BMC Womens Health. 2017; 17(1):43. PMC: 5474010. DOI: 10.1186/s12905-017-0393-z. View